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Abstract
The retinoblastoma protein (pRb) is a cell cycle regulator inactivated in most human cancers. Loss of pRb function results
from mutations in the gene coding for pRb or for any of its upstream regulators. Although pRb is predominantly known as a
cell cycle repressor, our data point to additional pRb functions in cell adhesion. Our data show that pRb regulates the
expression of a wide repertoire of cell adhesion genes and regulates the assembly of the adherens junctions required for cell
adhesion. We conducted our studies in osteoblasts, which depend on both pRb and on cell-to-cell contacts for their
differentiation and function. We generated knockout mice in which the RB gene was excised specifically in osteoblasts using
the cre-lox P system and found that osteoblasts from pRb knockout mice did not assemble adherens junction at their
membranes. pRb depletion in wild type osteoblasts using RNAi also disrupted adherens junctions. Microarrays comparing
pRb-expressing and pRb-deficient osteoblasts showed that pRb controls the expression of a number of cell adhesion genes,
including cadherins. Furthermore, pRb knockout mice showed bone abnormalities consistent with osteoblast adhesion
defects. We also found that pRb controls the function of merlin, a well-known regulator of adherens junction assembly, by
repressing Rac1 and its effector Pak1. Using qRT-PCR, immunoblots, co-immunoprecipitation assays, and immunofluores-
cent labeling, we observed that pRb loss resulted in Rac1 and Pak1 overexpression concomitant with merlin inactivation by
Pak1, merlin detachment from the membrane, and adherens junction loss. Our data support a pRb function in cell adhesion
while elucidating the mechanism for this function. Our work suggests that in some tumor types pRb inactivation results in
both a loss of cell cycle control that promotes initial tumor growth as well as in a loss of cell-to-cell contacts, which
contributes to later stages of metastasis.
Citation: Sosa-Garcı ´a B, Gunduz V, Va ´zquez-Rivera V, Cress WD, Wright G, et al. (2010) A Role for the Retinoblastoma Protein As a Regulator of Mouse Osteoblast
Cell Adhesion: Implications for Osteogenesis and Osteosarcoma Formation. PLoS ONE 5(11): e13954. doi:10.1371/journal.pone.0013954
Editor: Madhuri Kango-Singh, University of Dayton, United States of America
Received May 14, 2010; Accepted October 11, 2010; Published November 11, 2010
Copyright:  2010 Sosa-Garcı ´a et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Ponce School of Medicine institutional funds (RCMI Grant G12 RR003050) and American Cancer Society Institutional
Research Grant 93-032-13 to PGSC, and National Institutes of Health National Cancer Institute (NIH NCI) Grant U56CA118809 to PGSC and WDC. BSG is supported
by NIH National Institute of General Medical Sciences (NIGMS) MBRS-RISE Grant R25GM082406 (the content herein is solely the responsibility of the authors and
does not necessarily represent the official views of the NIGMS). WDC is further supported by grants 08BB-05 (Florida Department of Health), P01CA119997 (NCI),
R01CA90489 (NCI), and the Moffitt Cancer Center. PWH is supported by NIH/NIA grant AG020208. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: psantiago@psm.edu
Introduction
The retinoblastoma tumor suppressor protein (pRb) is a cell cycle
repressor inactivated in most human cancers [1–5]. While the cell
cycle regulatory pathway centered on pRb is inactivated in most
human cancers [1], pRb itself is specifically inactivated with high
frequency in a subset of human tumors, including retinoblastomas,
osteosarcomas, and small cell lung carcinomas [4]. pRb can also be
indirectly inactivated in other tumor types as a consequence of
alterations targeting genes coding for any of its several upstream
regulators such as CDK4, cyclin D and p16ink4a [6]. Indepen-
dently of the inactivationmechanism, a predominant trait of the loss
of pRb function is an inability to exit the cell cycle [7]. Interestingly,
studies conducted in retinoblastomas, osteosarcomas, and small cell
lung carcinomas point to an additional roleforpRb asa regulator of
cell adhesion. These tumor types show high frequencies of pRb
inactivation and are composed of cells that lack stable adherens
junctions, which are cadherin- and catenin-containing membrane
complexes required for cell adhesion. In retinoblastomas, adherens
junctions fail to anchor in the cortical actin cytoskeleton [8]. In
osteosarcomas and small cell lung carcinomas, anomalous localiza-
tion of adherens junction proteins has been observed, where
cadherins and b-catenin show weak cytoplasmic expression [9,10].
A strong correlation has been found in retinoblastomas and
osteosarcomas between abnormal adherens junctions and invasive
capacity [8,9], underscoring the notion that disruption of adherens
junctions-mediated cell adhesion is intimately related to metastasis.
The studies described above suggest that in some tumor types
pRb inactivation results in both a loss of cell cycle control, which
promotes initial tumor growth, as well as in a loss of cell-to-cell
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13954contacts, which later contributes to metastasis. This raises the
possibility that pRb, in addition to its well-characterized role as a
cell cycle repressor, may have a novel role as a regulator of cell-to-
cell contacts and adherens junction formation. Remarkably, studies
correlating pRb loss with adherens junction disruption have been
largely unnoticed, and while pRb has been best characterized as a
cell cycle regulator and its participation in developmental processes
is still the subject of intense research, no molecular mechanism has
been proposed to account for the correlation between pRb loss and
adherens junction abnormalities.
We studied the link between pRb and adherens junctions within
the context of osteoblast differentiation and bone formation,
processes that depend on both pRb and on the establishment of
cell-to-cell contacts [5,11–14]. We generated conditional pRb
knock-out mice in which the RB gene was excised specifically in
osteoblasts using the cre-lox P system, followed by analyzes of the
adhesive properties of osteoblasts obtained from these animals. In
agreement with previous reports [8–10], we found that knocking
out pRb production in osteoblasts had profound consequences on
cell adhesion, altering the expression profile of osteoblast cadherins
and other cell adhesion molecules, promoting disruption of
adherens junctions, and producing abnormalities in bone
structure. We found that pRb affects cell adhesion by at least
two mechanisms. First, pRb controls the expression of cell
adhesion genes. Second, pRb modulates the function of regulators
of adherens junction assembly such as the small Rho GTPase
Rac1 and the merlin tumor suppressor. Our data support a role
for pRb as a regulator of adherens junction formation and cell
adhesion and provide direct evidence that pRb depletion
profoundly affects the capacity of cells to interact with one
another.
Results
pRb-deficient osteoblasts do not undergo contact-
dependent growth arrest
To study the effect of pRb loss in murine osteoblast cell
adhesion, we produced primary cultures of these cells from
animals lacking pRb as a result of targeted homologous
recombination (pRb-deficient osteoblasts) as well as from their
control littermates (pRb-expressing osteoblasts). Primary cultures
were 3T3-immortalized (MC3T3) and used in subsequent
experiments. Phase contrast microscopy of MC3T3 cultures
showed that while pRb-expressing osteoblasts grow in culture to a
confluent monolayer, pRb-deficient osteoblasts continue to
proliferate past confluence, forming cell aggregates in which cells
pile one on top of the other (Fig. 1A). These aggregates become
apparent after 14 days in culture as crystal violet-stained foci
(Fig. 1B). No only do pRb-deficient MC3T3 osteoblasts
proliferate to higher densities, but they also have increased
capacity to mineralize the extracellular matrix in vitro.T h i s
capacity depends in turn on the density of bone-forming nodules,
which are active sites of bone mineral synthesis that arise by
clonal expansion of a subpopulation of osteoblasts within a
confluent monolayer. Staining of cultured osteoblasts with
alizarin red-S, which stains bone mineral deposition, revealed
increased mineralization by pRb-deficient osteoblasts relative to
pRb-expressing controls (figure 1C), suggesting an increased
density of bone-forming nodules in pRb-deficient cultures. This
increased mineralization capacity has also been reported for
primary pRb-deficient osteoblasts [15], demonstrating that pRb
loss could be sufficient to alter osteoblast properties indepen-
dently of additional mutations that drive immortalization or
transformation.
In order to compare the growth properties of pRb-expressing
and pRb-deficient osteoblasts in culture, primary and MC3T3
osteoblasts were plated at an initial density of 1610
5 cells per 6 cm
culture plate and counted once per week for three weeks. This
initial density produced confluent monolayers within 24 h after
plating. While pRb-expressing osteoblasts showed little prolifera-
tion following initial plating, pRb-deficient primary and MC3T3
osteoblasts grew in culture to a density approximately 3.5-fold
higher than their pRb-expressing counterparts (Fig. 1D).
To further test the proliferative behavior of these cells, MC3T3
osteoblasts were processed for BrdU immunocytochemistry before
reaching confluence (70–80%), at confluence (T0), and at 7, 14,
and 21 days beyond confluence (dbc). pRb-expressing and pRb-
deficient MC3T3 osteoblasts showed similar kinetics of BrdU
incorporation up until 7 dbc. After peaking at 7 dbc, pRb-
expressing osteoblasts showed a significant reduction at 14 dbc, a
time point at which pRb-deficient MC3T3 osteoblasts still showed
robust BrdU incorporation. BrdU-immunoreactive cells were
undetectable at 21 dbc in both pRb-deficient and pRb-expressing
MC3T3 osteoblast cultures (Fig. 1E). As expected, BrdU
incorporation in pRb-expressing MC3T3 osteoblasts at 7 dbc
was restricted to cells undergoing clonal expansion within bone-
forming nodules, while being rare at the periphery of the nodules
(Fig. 1F, top left, arrow). In contrast, pRb-deficient MC3T3 cells
showed robust BrdU incorporation in both the nodules and their
periphery (Fig. 1F, top right, arrow indicates bone forming
nodule). Together, these data show that pRb-deficient osteoblasts
grow to high densities relative to pRb-expressing osteoblasts, resist
contact-dependent growth arrest, and are poorly responsive to
conditions of high cell density that led to proliferative arrest of
their pRb-expressing counterparts. These observations suggest
that they are defective in sensing cell-to-cell contacts with
neighboring cells. pRb-deficient MC3T3 osteoblasts also showed
other traits indicative of transformation, such as forming tumors
when injected into mice and growing in an anchorage-indepen-
dent manner (Fig. S1).
pRb-deficient osteoblasts lack adherens junctions
The resistance of pRb-deficient osteoblasts to undergo contact-
dependent growth arrest could result from a failure to form
adherens junctions. Therefore, we examined the status of these
structures by immunocytochemical labeling of b-catenin, a
predominant adherens junction protein. While pRb-expressing
MC3T3 osteoblasts showed strong membrane-associated b-
catenin labeling, suggesting intact adherens junctions (Fig. 2, top
left), pRb-deficient MC3T3 osteoblasts showed a weak, diffuse
cytoplasmic staining, without any discernible membrane labeling
(Fig. 2, top right). The b-catenin staining observed in pRb-
deficient osteoblasts is indistinguishable from that reported in
osteosarcomas and small cell lung carcinomas [9,10]. To rule out
the possibility that the loss of adherens junctions observed in pRb-
deficient MC3T3 osteoblasts could be an artifact of the
immortalization process, we assessed the integrity of these
structures in primary osteoblasts. Similar to their 3T3-immortal-
ized counterparts, pRb-expressing primary osteoblasts showed
intact adherens junctions (Fig. 2, bottom left), while these
structures where absent in pRb-deficient primary osteoblasts
(Fig. 2, bottom right). This demonstrates that pRb loss could be
sufficient to alter osteoblast adhesive properties independently of
additional mutations that drive immortalization or transformation.
Knocking down endogenous pRb in pRb-expressing osteoblasts
with RB-shRNA also resulted in adherens junction loss (Fig. S2).
Interestingly, we also observed a decreased cell size in pRb-
deficient osteoblasts relative to their pRb-expressing counterparts.
pRb and Cell Adhesion
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their 3T3-immortalized derivatives, although it was more notable
in primary osteoblasts (figure 2, right panels). Although we
currently lack a mechanistic explanation linking pRb loss to
decreased cellular volume, we speculate that pRb loss could
impinge upon checkpoints beyond the G1/S transition, specifically
upon those that ensure that a cell does not progress to mitosis until
it has achieved a certain volume.
pRb-deficient osteoblasts show altered cadherin
expression
To determine if pRb loss affects the expression of osteoblast
cadherins, we performed immunoblot analyses of MC3T3
osteoblasts cultured until confluence. We found that while pRb-
expressing osteoblasts showed high OB-cadherin expression, pRb
deletion dramatically reduced the levels of this cadherin (Fig. 3A,
Figure 1. pRb-deficient osteoblasts do not undergo contact-dependent growth arrest. (A) Phase-contrast microscopy of osteoblasts
cultured until 14 days beyond confluence (dbc). pRb-expressing osteoblasts form confluent monolayers (left) while pRb-deficient ones proliferate
past confluence forming high-density cultures (right). Magnification=620. Bar=20 mm. (B) Triplicates of MC3T3 cultures stained with crystal violet at
14 dbc, showing foci formed by pRb-deficient osteoblasts (bottom), compared to pRb-expressing osteoblasts (top). (C) Matrix mineralization in
MC3T3 cultures. Phase contrast photomicrographs of alizarin red-S stained cultures at 106 showing increased extracellular matrix mineralization,
indicative of increased density of bone-forming nodules, in pRb-deficient osteoblasts (right) relative to pRb-expressing controls (left).
Magnification=610. Bar=20 mm. (D) Growth curves showing that both pRb-deficient primary (left) and MC3T3 (right) osteoblasts grew to a
saturation density ,3.5-fold higher than their pRb-expressing counterparts. Each data point represents the mean of 3 independent experiments 6
SEM. (E) BrdU immunocytochemistry of MC3T3 cells. Shown is percent of BrdU-positive cells, each data point representing the mean of 3
independent experiments 6 SEM. Time points chosen for analysis were: before confluence (70–80%), confluence (T0), and 7, 14, and 21 dbc (T7, T14
and T21, respectively). (F) BrdU immunocytochemistry showing BrdU incorporation in MC3T3 cells at 7 dbc. While BrdU incorporation in pRb-
expressing MC3T3 osteoblasts is restricted to bone forming nodules (arrow, top left), in pRb-deficient MC3T3 osteoblasts it is detected at both the
nodules (arrow) and at their periphery (top right). Bottom panels show total nuclei in the same visual fields stained with DAPI. Magnification=610.
Bar=20 mm.
doi:10.1371/journal.pone.0013954.g001
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elevated levels of N-cadherin relative to the basal levels observed in
pRb-expressing controls (Fig. 3A, middle panel), suggesting a
compensation for OB-cadherin loss by a proportional increase in
N-cadherin. In agreement with our b-catenin immunofluorescence
studies, immunoblots showed reduced b-catenin levels in pRb-
deficient osteoblasts relative to pRb-expressing controls (Fig. 3A,
bottom panel, the top band corresponds to b-catenin while lower
bands represent irrelevant background bands). qRT-PCR analyses
of MC3T3 osteoblasts cultured until confluence showed decreased
OB-cadherin and b-catenin mRNA and increased N-cadherin
mRNA levels in pRb-deficient osteoblasts relative to pRb-
expressing controls (Fig. 3B).
The increase in N-cadherin expression observed in pRb-
deficient osteoblasts is intriguing given the absence of adherens
junctions in these cells. Therefore, we investigated if the elevated
N-cadherin levels persist in pRb-null osteoblasts after prolonged
time in culture. Whereas pRb-expressing osteoblasts sustained
their basal N-cadherin expression at 14 dbc, N-cadherin
expression was decreased in pRb-deficient osteoblasts at this time
point (Fig. 3C, top panel). Furthermore, whereas pRb-expressing
osteoblasts show defined adherens junctions at 14 dbc, prolonged
culturing did not reestablish adherens junction formation in pRb-
deficient osteoblasts, as evidenced by the low levels of b-catenin
(Fig. 3C, second panel from top) and by their lack of membrane-
associated b-catenin immunostaining (Fig. 3D). Thus, we speculate
that in a pRb-null background N-cadherin becomes susceptible to
degradation in the absence of adherens junctions to which it can
attach. Finally, immunoblot analyses confirmed the pRb status of
pRb-expressing and pRb-null osteoblasts (Fig. 3C, third panel
from top). Together, our results show that pRb is required for the
proper regulation of OB- and N-cadherin expression in osteoblasts
and for their assembly into stable adherens junctions.
pRb knockout mice show abnormal calvarial bones
Next, we studied the calvarial bones in coronal sections of E18.5
pRb-null and control littermate skulls. To localize the calvarial
bone, sections were stained with alizarin red-S to identify areas of
active extracellular mineral deposition indicating the presence of
differentiated osteoblasts. Calvarial bones from control mice
displayed an osteoblast layer lining the cartilage at the base of
the skull (Fig. 4A, left). In pRb knockout mice this cartilage is
grossly disorganized and instead of a defined osteoblast layer,
scattered calcified nodules are apparent in the space that would
normally by occupied by cartilage (Fig. 4A, right). Immunohisto-
chemistry revealed that in control mice the osteoblast layer consists
of cells with membrane-associated b-catenin (Fig. 4B, top left).
Interestingly, clusters of cells showing nuclear b-catenin immuno-
reactivity were found within the disorganized cartilage in pRb
knockout mice (Fig. 4B, top right). pRb is thus required to properly
anchor b-catenin to the cell membrane also in vivo, and the
observed aberrant b-catenin localization due to pRb loss is not an
artifact of culture conditions.
The phenotype of the calvaria of pRb knockout mice is
consistent with pRb-deficient osteoblasts’ defect in establishing
cell-to-cell contacts, which could allow them to migrate away from
their proper position in the calvaria and to invade the adjacent
cartilage. Supporting this, pRb-deficient osteoblasts expressed
elevated levels of ezrin (Fig. 4C), a membrane-cytoskeleton linker
whose up-regulation is considered an indicator of osteosarcoma
metastasis [16,17].
pRb loss results in unrestrained Rac1 activity and merlin
inactivation
We examined the possibility that pRb could regulate cell
adhesion by controlling adherens junctions assembly, thus we
Figure 2. Abrogation of pRb expression disrupts adherens junctions. Immunocytochemical localization of b-catenin in MC3T3 (top) and
primary osteoblasts (bottom). pRb-expressing osteoblasts show strong b-catenin membrane-associated labeling along areas of cell-to-cell contact
(left) while pRb-deficient osteoblasts show a weak and diffuse labeling, without any clearly discernible membrane labeling (right).
Magnification=6100. Bar=1 mm.
doi:10.1371/journal.pone.0013954.g002
pRb and Cell Adhesion
PLoS ONE | www.plosone.org 4 November 2010 | Volume 5 | Issue 11 | e13954hypothesized that pRb controls the function of important
regulators of this process. We focused our attention on the small
Rho GTPase Rac1 and its effector, the p21-activated protein
kinase 1 (Pak1), and the merlin tumor suppressor. We had a solid
rationale for studying these molecules. First, Rac1 is a known
regulator of adherens junction stability and its unrestrained activity
disrupts adherens junctions [18]; second, pRb represses Rac1 in
osteoblasts [19,20]; third, merlin is a membrane protein required
for adherens junction assembly and contact-dependent growth
arrest [21]; and fourth, merlin is a Rac1 target that is inactivated
Figure 3. pRb deletion leads to abnormal cadherin expression. (A) Immunoblot of confluent cultures showing decreased levels of OB-
cadherin (top panel) and b-catenin (bottom panel) and increased levels of N-cadherin (middle panel) in pRb-deficient cells relative to pRb-expressing
controls. In the b-catenin panel, the top band corresponds to b-catenin while the lower bands are irrelevant background bands. Representative blots
of at least 3 independent experiments are shown. Equal loading of the lanes is shown by GAPDH levels for each individual immunoblot. (B) qRT-PCR
showing levels of OB-cadherin, N-cadherin, and b-catenin mRNAs in pRb-deficient osteoblasts relative to pRb-expressing osteoblasts (control bar).
Each bar represents the average of at least 3 independent experiments 6 SEM. Values were normalized against GAPDH. **, P,0.005; *, P,0.05. (C)
Representative immunoblots of at least 3 independent experiments of osteoblasts cultured until 14 dbc showing that the initial up-regulation of N-
cadherin levels observed in pRb-deficient osteoblasts is not sustained after prolonged culture time (top). b-Catenin expression is also reduced in pRb-
deficient osteoblasts at 14 dbc (second from top). The pRb status of these cells was confirmed (third panel from top), and equal loading of the lanes is
demonstrated by GAPDH levels (bottom). (D) Immunofluorescent labeling of b-catenin showing lack of adherens junctions in pRb-deficient
osteoblasts cultured until 14 dbc (right), compared to pRb-expressing osteoblasts cultured in the same conditions (left). Magnification=6100.
Bar=1 mm.
doi:10.1371/journal.pone.0013954.g003
pRb and Cell Adhesion
PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e13954upon phosphorylation at serine 518 (Ser518) by Rac1s effector
Pak1 [22–24]. Therefore, we postulated that pRb represses Rac1
and Pak1 expression, thus allowing merlin activity and adherens
junction assembly at the cell membrane. We tested this by
assessing Rac1 and Pak1 expression with immunoblots and qRT-
PCR. Supporting our hypothesis, levels of Rac1 and Pak1 proteins
and mRNA were increased in pRb-deficient osteoblasts compared
with pRb-expressing controls (Figs. 5A and B).
Next, we compared pRb-expressing with pRb-deficient MC3T3
osteoblasts in terms of merlin function. Immunoblots showed that
merlin migrates as a doublet (Fig. 5C), consistent with it being a
phosphoprotein existing in hyper- and hypophosphorylated forms
[22–24]. At the time of confluence, merlin was detected
predominantly as the slower-migrating hyperphosphorylated form
in both pRb-expressing and pRb-deficient MC3T3 cultures
(Fig. 5C, left panels). However, we observed an increase in the
Figure 4. Osteoblasts in the calvarial bone of conditional pRb knockout mice show abnormal b-catenin staining. (A) Coronal skull
sections of embryonic day 18.5 (E18.5) mice stained with alizarin red-S showing location of differentiated osteoblasts. In calvarial bones from pRb-
expressing mice (left), osteoblasts form a layer lining the cartilage at the base of the skull, while in pRb knockout mice (right) scattered calcified
nodules are found within a grossly disorganized cartilage. Magnification=64. Bar=2 mm. (B) b-Catenin immunohistochemistry of calvarial bones of
pRb-expressing and pRb knockout mice. Osteoblasts in calvarial bones from pRb-expressing mice show membrane b-catenin (top left). Clusters of
cells showing strong nuclear immunoreactivity for b-catenin were found within the disorganized cartilage in pRb knockout mice (top right). Negative
controls processed without primary antibody are shown (bottom). OL, osteoblast layer; E, epithelium; C, cartilage; Br, brain. Magnification=6100.
Bar=1 mm. (c) A representative immunoblot showing increased ezrin expression in cultured pRb-deficient osteoblasts relative to pRb-expressing
controls.
doi:10.1371/journal.pone.0013954.g004
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expressing MC3T3 osteoblasts at 14 dbc (Fig. 5C, top right). On
the other hand, merlin remained predominantly hyperphosphory-
lated in pRb-deficient osteoblasts at 14 dbc (Fig. 5C, bottom right).
It is noteworthy that appearance of the hypophosphorylated
merlin in pRb-expressing osteoblasts at 14 dbc coincided with the
decreased BrdU incorporation seen in these cells at this time point
(Fig. 1E). These observations agree with previous reports showing
that hypophosphorylated merlin is the active anti-proliferative
form associated with contact-dependent growth arrest [25]. Calf
intestinal phosphatase (CIP) treatment of protein lysates confirmed
that the merlin doublet is due to phosphorylation, since CIP
eliminated the slower-migrating band whereas phosphatase
inhibitors reversed this effect (Fig. 5D).
Since merlin attachment to the cell membrane is essential for its
function, we tested the effect of pRb on merlin localization.
Immunocytochemical localization of merlin revealed two distinct
cellular pools in pRb-expressing osteoblasts: a strong punctuated
perinuclear staining pattern and a membrane-associated staining
(Fig. 5E, left), the latter being consistent with merlin function in
Figure 5. pRb loss results in unregulated Rac1, Pak1, and merlin function. (A) Immunoblot showing increased Rac1 (left) and Pak1 (right)
levels in pRb-deficient osteoblasts relative to pRb-expressing controls. Equal loading of lanes is shown by GAPDH levels (bottom panel for each
protein). (B) qRT-PCR showing the same upregulation at the mRNA level in pRb-deficient osteoblasts relative to pRb-expressing osteoblasts (control
bar). Each bar represents the average of at least 3 independent experiments 6 SEM. Values were normalized against GAPDH. **, P,0.005; *, P,0.05.
(C) Immunoblot showing an increased ratio of the hypophosphorylated to the hyperphosphorylated merlin in pRb-expressing MC3T3 osteoblasts at
14 dbc. (D) Whole protein extracts from pRb-expressing MC3T3 osteoblasts at 14 dbc treated with calf intestinal phosphatase (CIP) before
immunoblot analysis for merlin. CIP treatment eliminated the slower-migrating band, whereas CIP inhibitors reversed this effect. Lane 1, untreated
lysates; lane 2, lysates treated only with CIP buffer; lane 3, lysates treated with CIP; lane 4, lysates treated with CIP plus inhibitors. (E)
Immunocytochemical localization of merlin in MC3T3 cells. In pRb-expressing MC3T3 osteoblasts merlin staining reveals a strong, punctuated
perinuclear pattern as well as a membrane staining (left). In pRb-deficient MC3T3 osteoblasts cells the membrane staining is lost (right).
Magnification=6100. Bar=1 mm. (F) Merlin was immunoprecipitated from whole protein lysates followed by immunoblots of the
immunoprecipitates with antibodies against merlin, b-catenin, N-cadherin, and a-tubulin. In pRb-expressing MC3T3 osteoblasts, merlin is
immunoprecipitated predominantly as a hypophosphorylated form together with adherens junction components b-catenin and N-cadherin. In pRb-
deficient MC3T3 osteoblasts, merlin is immunoprecipitated predominantly as a hyperphosphorylated form together with a-tubulin.
doi:10.1371/journal.pone.0013954.g005
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staining was apparent in pRb-deficient osteoblasts (Fig. 5E, right),
suggesting that merlin becomes detached from adherens junctions
in pRb-deficient osteoblasts. To confirm this, merlin was
immunoprecipitated from whole cell lysates using a merlin-specific
antibody, followed by immunoblotting the precipitates with
antibodies against merlin, b-catenin, N-cadherin, and a-tubulin.
Merlin was immunoprecipitated as a doublet in both pRb-
expressing and pRb-deficient osteoblasts. However, the hypopho-
sphorylated form predominated in pRb-expressing osteoblasts
while the hyperphosphorylated form predominated in pRb-
deficient osteoblasts (Fig. 5F, top), suggesting merlin inactivation
in pRb-deficient osteoblasts. While in pRb-expressing osteoblasts
merlin co-immunoprecipitated with adherens junction compo-
nents b-catenin and N-cadherin, in pRb-deficient osteoblasts it co-
immunoprecipitated with a-tubulin (Fig. 5F, second and third
panels from top, bottom panel), which is consistent with merlin
having a tubulin binding site that is exposed only in the inactive
form due to misfolding induced by phosphorylation in Ser518
[26,27]. Additional studies conducted in the human pRb-deficient
osteosarcoma cell line Saos-2 showed that pRb expression is
necessary and sufficient to promote merlin activation (Fig. S3).
In order to correlate Rac1 activity with merlin function and
adherens junction integrity, we manipulated Rac1 activity in pRb-
expressing osteoblasts by transfecting them with plasmid vectors
encoding a constitutively activated Rac1 mutant not susceptible to
inhibition by pRb (RacV12). We used stable transfectants to
investigate the effects of unrestrained Rac1 activity on contact-
dependent growth arrest, adherens junction formation, and merlin
intracellular localization and phosphorylation. Phase-contrast
microscopy (Fig. 6A) and growth curves (Fig. 6B) showed that
osteoblasts stably expressing RacV12 grew in culture to a cell
density significantly higher than osteoblasts transfected with
control vector and comparable to pRb-deficient osteoblasts. A
comparable increase in cell density was observed in pRb-
expressing osteoblasts transfected with a dominant negative
mutant version of the Rac1 repressor the cyclin-dependent kinase
5 (Cdk5) [19,20,28,29].
Using immunocytochemistry, we observed that the membrane
staining for b-catenin and merlin is lost in osteoblasts expressing
either RacV12 or dnCdk5. Instead, these cells showed a weak,
diffuse, and cytoplasmic labeling for b-catenin, whereas merlin
staining revealed only the perinuclear form (Fig. 6C). These results
show that unrepressed Rac1 activity in pRb-expressing osteoblasts
mimics pRb loss by inhibiting merlin function and disrupting
adherens junctions.
To assess the phosphorylation status of merlin in pRb-
expressing osteoblasts with unrestrained Rac1 activity, merlin
was immunoprecipitated from whole protein lysates followed by
immunoblotting with a phospho-specific antibody that recognizes
merlin when it is phosphorylated in Ser518. Consistent with our
hypothesis that pRb promotes merlin activity by blocking Rac1/
Pak1, we observed increased merlin phosphorylation in pRb-
deficient osteoblasts compared with pRb-expressing osteoblasts
transfected with control vector (Fig. 6D). As expected, merlin is
highly phosphorylated in pRb-expressing osteoblasts transfected
with RacV12 and, consistent with Cdk5s repressive effect on Rac1,
in pRb-expressing osteoblasts transfected with dnCdk5 (Fig. 6D).
These results show that unrestrained Rac1 activity leads to merlin
phosphorylation at Ser518 concomitant with its detachment from
the cell membrane. Finally, we observed that cells expressing
either dnCdk5 or RacV12 formed crystal violet-stained foci,
showing that these cells do not undergo contact-dependent growth
arrest (Fig. 6E).
Next, we examined the expression levels of adherens junction
components in pRb-expressing osteoblasts stably expressing either
dnCdk5 or RacV12. Immunoblots showed that unrestrained Rac1
activity due to the action of dnCdk5 or RacV12 reduced b-catenin
and N-cadherin levels (Fig. 6F, top and second from top panels).
Consistent with our previous observation that Pak1 is up-regulated
in pRb-deficient osteoblasts (see Fig. 5A) and with the hypothesis
that pRb blocks Rac1/Pak1 activity, we observed increased Pak1
levels in pRb-deficient osteoblasts compared with pRb-expressing
controls (Fig. 6F, third panel from top). Furthermore, Pak1 levels
were dramatically increased in pRb-expressing osteoblasts trans-
fected with RacV12 or dnCdk5 (Fig. 6F, third from top). These
changes are consistent with merlin phosphorylation on Ser518 in
pRb-expressing osteoblasts transfected with either dnCdk5 or
RacV12 and in pRb-deficient osteoblasts (Fig. 6D). Finally, we
observed that blocking Rac1 activity with a dominant negative
Rac1 (RacN17) opposed the effects of unrestrained Rac1 activity
by partially reestablishing contact-dependent growth arrest and
adherens junction formation (Fig. S4).
Microarray studies show that pRb regulates expression of
cell adhesion genes
To test whether pRb regulates cell adhesion-associated gene
expression globally, we compared pRb-expressing and pRb-
deficient osteoblasts in terms of gene expression patterns using
microarray analysis. Microarray data were deposited with the
National Center for Biotechnology Information Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo/, accession number
GSE19299), and is represented in Tables S1, S2, S3, S4, S5, S6.
We used two methods to analyze the microarray data. First, using
a canonical pathway database, we performed a cellular pathway
analysis that showed that 8 of the top 10 cellular processes affected
by pRb are related to cell adhesion, indicating a strong influence
by pRb on cell adhesion (Table S1). Second, using the Gene
Ontology database to identify cell adhesion-related genes, we
obtained 1719 individual probe sets corresponding to genes
involved directly or indirectly in cell adhesion. Of these, 1054
(61%) were significantly altered by pRb with a false discovery rate
(FDR) of ,0.0320 (FDR ,0.05 is statistically significant). Table
S2 shows cell adhesion genes activated by pRb while table S3
shows cell adhesion genes repressed by pRb. Other approaches
such as GeneGo (Table S4), Gene Set (Table S5) and Gene Set
Enrichment analyses (Table S6) also ranked cell adhesion high on
the list of pRb-regulated processes. Together, these results show
that pRb dramatically affects the transcription of a wide array of
cell adhesion genes.
qRT-PCR validated pRb regulation of several genes
involved in cell adhesion
Eight up-regulated and 9 down-regulated cell adhesion genes
were chosen from the microarray list of pRb-affected cell adhesion
genes and validated by qRT-PCR (Fig. 7). Up-regulated genes
chosen for validation included those coding for adherens junction
components (a- and d-catenins, cadherin1/E-cadherin/CDH1, nf2/
merlin, cadherin-26, and OB-cadherin). Also chosen for validation was
pannexin 3, a gap junction protein with tumor suppressive capacity
[30]. On the other hand, pRb-repressed genes chosen for
validation included cancer cell surface markers involved in
promoting invasiveness and metastasis such as melanoma cell
adhesion protein (mcam), mesothelin, metadherin, and podocalyxin-like 2
(podx12), among others [31–38]. All 9 of the pRb-repressed genes
were validated (P,0.05). This was expected given that pRb is a
well-characterized transcriptional repressor [39] and gives us
pRb and Cell Adhesion
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transcripts repressed by pRb according to microarray data was
Pak1, validated at both the mRNA and protein levels (Figs. 5A and
5B). In contrast, only 4 of the 8 genes predicted to be up-regulated
by pRb (cadherin1/E-cadherin/CDH1, wisp2, pannexin 3, and cadherin
26) were validated (P,0.05). OB-cadherin (cadherin-11) was validated
both at the mRNA and protein levels (Figs. 3A and 3B). The other
four genes (nf2/nf2, ctnnd1, ctnnal1 and rnd3) were not significantly
activated by pRb. This suggests that pRb could be regulating the
expression of these genes acting through more complex or indirect
mechanisms, for example by controlling the expression, function
or DNA binding capacity of transcriptional regulators for these
genes.
Discussion
Carcinogenesis-associated mutations disrupt many aspects of
cellular function, cell cycle control and cell adhesion being among
them. This raises the possibility that the loss of intercellular
adhesion leading to metastasis could also result from the functional
disruption of cell cycle regulators at earlier stages of carcinogen-
esis. Supporting this idea, several reports correlate pRb mutational
Figure 6. Unrestrained Rac 1 activation in pRb-expressing osteoblasts mimics pRb loss by perturbing cell adhesion. Phase contrast
photomicrographs at x10 (A) and growth curves (B) showing that pRb-expressing MC3T3 osteoblasts stably expressing RacV12 or dnCdk5 grow in
culture to a higher density relative to pRb-expressing MC3T3 osteoblasts transfected with control vector (CV). Bar in (A)=2 0mm. Each point in (B)
represents the mean of 3 independent experiments 6 SEM. (C) Immunocytochemical analysis showing loss of membrane-associated b-catenin (top)
and merlin (bottom) in pRb-expressing MC3T3 osteoblasts transfected with either RacV12 or dnCdk5, as compared to CV-transfected cells. These cells
show a staining pattern comparable to that observed in pRb-deficient MC3T3 osteoblasts (last panel to the right). Magnification=6100. Bar=1 mm.
(D) Merlin was immunoprecipitated from whole protein lysates with a merlin-specific antibody followed by immunoblots with a merlin phospho-
specific antibody recognizing Ser518. Merlin phosphorylation was observed in pRb-expressing osteoblasts cells transfected with dnCdk5 or Rac V12,
as well as in pRb-deficient osteoblasts. (E) Triplicates of crystal violet-stained plates showing foci formation in pRb-expressing osteoblasts transfected
with dnCdk5 5 or RacV12 and in untransfected pRb-deficient osteoblasts, as compared with CV-transfected cells. (F) Immunoblots showing decreased
expression of b-catenin and N-cadherin, and increased Pak1 expression in pRb-expressing osteoblasts transfected with dnCdk5 or RacV12, as well as
in untransfected pRb-deficient osteoblasts, relative to CV-transfected cells. Experiments were conducted in osteoblasts cultured until 14 dbc.
doi:10.1371/journal.pone.0013954.g006
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were chosen for validation; x-axis represents the fold activation of gene expression in the presence of pRb (pRb+/+ osteoblasts divided by pRb2/2
osteoblasts). Negative values mean the gene was repressed by pRb, while positive values indicate activation. Each bar corresponds to a different
gene. All 9 genes repressed by pRb in microarray analyses were validated (P,0.05) while only 4 of the putative pRb-activated genes were validated
(P,0.05). (B) We were unable to perform qRT-PCR on cdh26. Instead, this figure shows a semi-quantitative RT-PCR analysis of mesothelin and cdh26
levels. Results verify that cdh26 is up-regulated and mesothelin is down-regulated by pRb.
doi:10.1371/journal.pone.0013954.g007
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confirm and extend these reports by showing that abrogating pRb
expression in murine osteoblasts leads to aberrant expression of
surface cadherins, disruption of adherens junctions, and loss of
contact-dependent growth arrest. We propose that pRb loss could
contribute to tumor formation not only by leading to a breakdown
in cell cycle control but also by allowing cells to circumvent the
restriction imposed on their proliferation by the establishment of
cell-to-cell contacts.
Osteoblastic differentiation strongly depends on cell-to-cell
interactions. Osteoblasts originate from pluripotent mesenchymal
stem cells that differentiate into stroma, adipocytes, myoblasts,
chondroblasts, fibroblasts, or osteoblasts [40,41]. Stem cells that
commit to osteoblastic differentiation are sorted from other
mesenchymal cells and align with and adhere to each other.
Cadherins mediate these cell-to-cell attachments, and osteopro-
genitor cells express a changing repertoire of cadherins that
provide cues for their differentiation into mature osteoblasts
[12,42]. Here we showed that adherens junction loss in pRb-null
osteoblasts is accompanied by abnormal expression patterns of
OB- and N-cadherins, which are the predominant osteoblasts
cadherins. This suggests that pRb is required to temporally
regulate these changes such that expression of specific cadherins is
triggered with the right timing during differentiation. pRb loss
could hamper the proper homotypical intercellular contacts,
resulting in defective osteoblast differentiation and function with
consequent disruption of bone integrity or formation of bone
tumors. The structural defects observed in the calvaria of pRb
knockout mice support this hypothesis and are suggestive of
osteoblasts that are incapable of adhering to each other. Given the
central role that both pRb and cell-to-cell interactions play in
osteoblast differentiation [4,15,43], we postulate that pRb’s role in
osteoblast differentiation could be related to its capacity to
promote the proper cell-to-cell contacts among differentiating
osteoblasts.
We showed that pRb-deficient cells have significantly reduced
expression of OB-cadherin, which appeared among the transcripts
that are up-regulated by pRb in our microarray assays, with an
average fold-induction by pRb of 4.45 (P=0.000). We also found
cadherin1/E-cadherin/CDH1 to be up-regulated by pRb. There
is a precedent for transcriptional regulation of cadherins by pRb.
It has been shown that pRb up-regulates transcription of the
cadherin1/E-cadherin/CDH1 gene via an interaction with the AP-2
transcription factor, a well-known pRb-binding partner and
transcriptional co-activator [44]. Supporting this, we found
cadherin1/E-cadherin/CDH1 to be dramatically up-regulated by
pRb in our microarray assays, with an average fold-induction of
11.83 over pRb-null cells (P=0.000, validated by qRT-PCR).
However, it remains to be clarified whether other genes found in
our microarray studies to be up- or down-regulated by pRb are
targets of known pRb binding proteins and transcriptional co-
regulators such as AP-2 and E2F. On the other hand, the increase
in N-cadherin observed in pRb-deficient osteoblasts is more
difficult to explain. N-cadherin did not appear among the
transcripts regulated by pRb in our microarrays, suggesting that
a regulation of N-cadherin by pRb is indirect via other factors.
However, this change in cadherin expression is strikingly
reminiscent of the cadherin switch occurring during the epithe-
lial-to-mesenchymal transition (EMT) that is part of oncogenic
transformation. Indeed, pRb abrogation in several epithelial cell
lines has been shown to induce changes associated with an EMT,
including such a cadherin switch in which cadherin1/E-cadherin/
CDH1 is replaced by N-cadherin [45-47]. While a cadherin switch
in epithelial cells could trigger metastasis, a similar switch in
osteoblasts could profoundly disrupt bone morphogenesis and
promote osteosarcoma formation by affecting the cell-to-cell
interactions that drive osteogenic differentiation. Our data
showing a switch from OB- to N-cadherin upon pRb loss are
fully consistent with other reports and lend credence to the
hypothesis that pRb could prevent cancer spreading and
metastasis by promoting cell-to-cell adhesion.
pRb appears to have a global influence on cell adhesion beyond
the control of cadherin genes. Our microarrays show that pRb
controls expression of a wide range of cell adhesion genes, thus
having a strong influence over cellular processes related to
adhesion. We observed that pRb promotes the expression of
genes involved in the promotion of adhesion of differentiated cells
while repressing the expression of genes associated with invasive-
ness and metastasis and whose products could be used by cancer
cells to engage in transient interactions along their migration
pathways. Furthermore, our microarray data show that pRb up-
regulates the expression of genes coding for proteins involved in
several types of interactions between the cell and its surroundings,
such as integrins and gap and tight junction proteins.
Our data also suggest a model integrating pRb, Rac1, Pak1, and
merlin in adherens junction assembly (Fig. 8). pRb could promote
adherens junction assembly by regulating the expression of
adherens junction genes and/or by repressing Rac1 activity.
pRb can repress Rac1 by down-regulating Pak1 levels or,
alternatively, via Cdk5, a known Rac1 repressor [19,20,28,29].
Since Cdk5 activity can be triggered by pRb in osteoblasts [19,20],
we used dnCdk5 as an additional tool to induce unrestrained Rac1
activity, and it yielded results that are indistinguishable from pRb
deletion or transfection with RacV12. However, we have no
conclusive data showing that Cdk5 intervention is necessary for
the pRb-dependent repression of Rac1/Pak1.
Although we have shown that abrogating pRb function in
osteoblasts has a disruptive effect on cell adhesion, it remains to be
established whether altering the function of upstream components
of the pRb pathway such as CDK4, cyclin D, and p16ink4a, will
have similar consequences for intercellular adhesion. At this
moment it is unclear whether a function on cell adhesion is unique
for pRb or if it is shared with other components of the pRb
Figure 8. Possible mechanisms by which pRb could regulate
cell adhesion. pRb regulates transcription of adherens junction and
cell adhesion genes (1). pRb also regulates cell adhesion by repressing
Rac1, a repression that allows merlin activation and adherens junction
assembly. pRb achieves this by down-regulating the expression of Pak1
(2) or by activating Cdk5 (3). The relevance of (3) for the pRb-mediated
assembly of adherens junctions is still unclear.
doi:10.1371/journal.pone.0013954.g008
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This is an important question that must be addressed in follow-up
studies since mutations in CDK4, cyclin D, and p16ink4a are
linked to the molecular etiology of a wider spectrum of human
tumors than mutational inactivation of pRb itself [48]. Given the
intimate functional interrelatedness among these proteins, it would
be expected that loss of p16ink4a with concomitant pRb
inactivation, for example, would be functionally equivalent to
pRb loss. Interestingly, studies on the molecular etiology of lung
cancer have shown that the consequences of mutating pRb could
differ profoundly, both biochemically and in terms of phenotype,
from the consequences of mutating p16ink4a. For example,
although it is accepted that inactivation of only one component of
the pRb pathway is required for lung tumorigenesis, the subset of
tumors that arises as a consequence of pRb loss is different from
the one that arises due to p16ink4a loss [48]. This illustrates that
inactivating different components of the same pathway does not
necessarily results in the same phenotype.
In summary, this study contributes to the characterization of a
non-traditional role for pRb as a regulator of cell adhesion and
provides mechanistic insights for this role. Conceptually, a dual
role for pRb as a regulator of both cell cycle progression and
adherens junction assembly could be of central importance in the
orchestration between cell proliferation and cell adhesion, an
orchestration that may be pivotal for tissue morphogenesis. A
disruption of pRb function with the resulting breakdown of this
orchestration could be at the core of the molecular etiology of
some human cancers. This dual role for pRb implies that pRb
inactivation could play a significant role not only during initial
tumor formation by extending the replicative capacity of mutant
cells but also at later stages of tumorigenesis, by disrupting cell-to-
cell interactions consequently leading to metastasis. This dual role
for pRb could contribute to what has been described by some
cancer researchers as ‘‘the hope to achieve an understanding of the
complex process of neoplastic transformation at the cellular level
in terms of a small number of genetic changes’’ [49].
Materials and Methods
Ethics statement
All animal studies were conducted using procedures approved
by the Institutional Animal Care and Use Committee of Tufts
University & Tufts Medical Center and covered under protocol
number B2009-124.
Animals
The flox19-RB1 mice were obtained from the laboratory of
Doug Hanahan (San Francisco, CA) and maintained in a C57BL/
6 background. 2.3- and 3.6-Col1a1-Cre transgenic mice were
obtained from the laboratory of Barbara Kream (Farmington,
CT). The F1 RBf19/WT;Col1a1-Cre mice were self-crossed and
the resulting F2 mice were used in our studies.
Calvarial cell preparation and cultures
Primary osteoblasts were isolated from embryonic day 18.5
(E18.5) mice calvarial bone. Briefly, calvariae (topmost skull bones)
were removed, rinsed with PBS, and digested in 0.05% Trypsin/
EDTA plus 0.1% collagenase P (Boehringer Mannheim) at 37uC
with shaking. Cell suspensions were collected from the digestion
reaction at 10-min intervals and centrifuged at 1,600 g for 5
minutes. The resulting cell pellet was resuspended in minimum
essential medium-alpha (a-MEM) (GIBCOH/Invitrogen) supple-
mented with 10% fetal bovine serum (FBS, Invitrogen) and 1%
penicillin-streptomycin (Sigma), and plated in 6-cm culture plates.
Osteoblast differentiation was induced by culturing them in the
presence of 0.01 M b-glycerophosphate, 100 mM I-ascorbic acid
and 0.1 mM dexamethasone (Sigma). 3T3-immortalized osteo-
blasts (MC3T3 cells) were obtained by culturing primary
osteoblasts using the 3T3 protocol, in which 3610
5 cells were
plated in 6-cm culture plates and passaged every 3 days. The
population doubling level during each passage was calculated
according to the formula log (final cell number/3610
5)/log2.
MC3T3 cells were maintained in a-MEM supplemented with
10% FBS and 1% penicillin-streptomycin.
Plasmids and transfections
Plasmids pEBG-RacV12 and pEBG-RacN17 (from the labora-
tory of John Blenis) have been previously described [50]. Plasmid
pCDNA3-dnCdk5 was a gift from Li-Huei Tsai. MC3T3 cells
were transfected at 70-80% confluence with FuGENEH (Roche)
following manufacturer’s specifications, selected with 0.5 mg/ml
puromycin, and maintained under selection medium for the
duration of the experiments.
Growth curves
Cells were plated in triplicate at an initial density of 10
5 cells per
6-cm culture plate. Cells were trypsinized and counted on a weekly
basis for 3 consecutive weeks.
Focus and colony assays
To determine focus formation, MC3T3 cells were plated at a
density of 10
5 cells per 6-cm culture plate, grown to confluence,
and maintained without splitting for 14–21 days. Medium was
changed every 3 days. Cultures were then rinsed with PBS and
stained with 4 mg/ml crystal violet in 10% methanol. For colony
formation in soft agar, MC3T3 cells were plated at the same
density as described above in 0.4% Sea PlaqueH low-gelling
temperature agarose (American Bioanalytical) in a-MEM supple-
mented with 10% FBS. The number of colonies per visual field
was scored 21 days later.
Tumorigenicity assay
For in vivo tumor formation, 1610
6 MC3T3 cells were injected
into flanks of 4- to 6-week-old SCID/NCr (BALB/C) female
mice (National Cancer Institute). Three mice were used for each
cell type tested. Tumor formation was scored 3 weeks after
injection.
BrdU immunocytochemistry
Cells grown in chambered tissue culture slides were cultured for
24 h in the presence of 10 mM BrdU before being processed for
BrdU immunocytochemistry at various time points. We used the
BrdU in situ detection kit (BD Pharmingen), according to
manufacturers specifications. Briefly, cells were fixed for 15
minutes in 2% paraformaldehyde/0.2% glutaraldehyde in PBS
and permeabilized for 30 minutes in 1% bovine serum albumen
(BSA)/0.2% Triton X-100 in PBS, followed by incubation in BD
Retrieve Antigen solution A at 89uC for 10 minutes. Chamber
slides were cooled to room temperature, washed 3 times with PBS,
and incubated for 1 h at room temperature with biotinylated anti-
BrdU antibody diluted 1:10 in 1% BSA/0.2% Triton X-100 in
PBS. Slides were then washed 3 times in PBS and incubated for 30
minutes at room temperature with streptavidin-conjugated Alexa
499 diluted 1:20 in 1% BSA/0.2% Triton X-100 in PBS. Slides
were washed again 3 times with PBS, counterstained with Hoechst
33258 for 1 minute, rinsed 5 times with distilled water, and
mounted in Fluoromount-G (Southern Biotech).
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osteoblast cultures
Paraffin-embedded skull coronal sections obtained from E18.5
mice were deparaffinized by heating at 58uC–60uC for 30 minutes,
followed by three 2-min washes in xylene. Sections were
rehydrated with a series of washes of 100%, 95%, 70%, and
50% ethanol, followed by a final wash in distilled water. They
were then stained in a 0.5% alizarin red-S solution (pH 4.2) for 5–
30 minutes, rinsed 3–5 times with distilled water, allowed to air-
dry, and mounted with Cytoseal 60 (Stephens Scientific). Staining
of cultures was done by incubating in 0.5% alizarin red-S solution
for 5 minutes, followed by rinsing with distilled water and air-
drying.
Western immunoblotting
Protein expression was detected by immunoblotting following
standard procedures. Cells were lysed in 100–200 mL of ELB
(50 mM HEPES, pH 7.2, 250 mM NaCl, 2 mM EDTA, 0.1%
NP-40, 1 mM dithiothreitol) plus protease and phosphatase
inhibitors (1 mg/ml of aprotinin, 1 mg/ml of leupeptin, 100 mg
of phenylmethylsulfonyl fluoride, 4 mM sodium orthovanadate,
2 mM sodium pyrophosphate). Lysate protein concentration was
determined by BioRad protein assay. For immunoblotting, 50-
100 mg of protein were separated by SDS-PAGE, transferred to
nitrocellulose, and immunoblotted with the indicated primary
antibody. Secondary antibodies used were horseradish peroxidase-
conjugated donkey anti-mouse or donkey anti-rabbit (Jackson
Immunosciences). For immunoprecipitations, protein lysates (100–
200 mg) were immunoprecipitated with the indicated antibody
overnight at 4uC, protein A-sepharose CL-4B beads (30 mL
Amersham Biosciences) were added for 1 h, and following
centrifugation beads were then washed four times with ELB lysis
buffer and separated by SDS-PAGE. For calf intestinal phospha-
tase (CIP) treatment, protein lysates (50 mg) were treated with 50
units of CIP overnight at 37uC and then separated by SDS-PAGE.
The CIP inhibitors used were 20 mM Na3VO4, 2 mM sodium
pyrophosphate, and 40 mM sodium fluoride.
Immunofluorescence
Cells grown in chambered culture slides were rinsed 3 times
with cold PBS, fixed in methanol for 10 minutes on ice, and
allowed to air-dry. After another rinse in PBS, cells were blocked
with 10% BSA in PBS for 30 minutes at 4uC, rinsed again in PBS,
incubated for 1 h at room temperature with primary antibody
diluted 1:100 in PBS containing 1% BSA and 0.2% Triton X-100,
and then briefly rinsed with cold PBS and incubated for 1 h at
room temperature with either Alexa Fluor 546-conjugated goat
anti-rabbit or Alexa Fluor 488-conjugated goat anti-mouse
secondary antibody (Molecular Probes) diluted 1:200 in PBS.
DNA was stained with Hoechst 33258 for 1 minute. Cells were
then rinsed 5 times with distilled water and mounted with
Fluoromount-G. We used a Nikon Eclipse 80i microscope to
observe slides and a SPOT RT KE camera using the SPOT
software version 4.1 for Mac for image acquisition.
Small interfering RNA
A short hairpin-interfering RNA targeting the RB gene (RB-
shRNA) was designed and cloned using the siSTRIKE U6 Hairpin
Cloning System from Promega, following manufacturer’s instruc-
tions. We used the siRNA Target Designer (www.promega.com/
siRNADesigner/) to design oligonucleotides using the RB gene as
the input sequence. The following oligonucleotides targeting
position 3168–3186 within the RB gene were synthesized
(Integrated DNA Technologies): 59-accggaccctaacacagtatatttcaa-
gagaatatactgtgttagggtcctttttc-39 and 59-tgcagaaaaaggaccctaaca
cagtatattctcttgaaatatactgtgttagggtc-39. Oligonucleotides were an-
nealed, ligated and cloned in the psiSTRIKE
TM vector.
Constructs were transfected as described above.
Immunohistochemistry
E18.5 skull coronal sections were deparaffinized and rehydrated
as described above. After rehydration, tissue sections were
incubated for 30 minutes in 0.3% H2O2 in PBS to inactivate
endogenous peroxidase activity, incubated for 15 minute at 37uC
in 4 N HCl for antigen retrieval, blocked for 1 h at room
temperature in 3% BSA in PBS, and then incubated with primary
antibody in a humid chamber for 3 h at room temperature.
Primary antibodies were diluted 1:100 in 3% BSA in PBS. Tissue
sections were then washed 3 times in PBS and incubated for 2 h at
room temperature with horseradish peroxidase-conjugated donkey
anti-mouse or donkey anti-rabbit secondary antibodies (Jackson
Immunosciences), followed by 4–5 washes in PBS and then
incubated with 3,39-diaminobenzidine in 0.05 M Tris-HCl
(pH 7.6) for 5–30 minutes until the appearance of a dark brown
precipitate, followed by hematoxylin counterstaining for 1 minute
and 3–4 washes in distilled water. Tissue sections were then
allowed to air dry for 5 minutes and mounted with Cytoseal 60.
Antibodies used for immunoblotting, immunofluorescence, and
immunohistochemistry were anti-b-catenin (H-102 Santa Cruz,
sc-7199), anti-N-cadherin (BD Transduction Laboratories,
#610920), anti-pRb (BD Pharmingen, #554136), anti-PAK (N-
20 Santa Cruz, sc-882), anti-Rac1 (C-11 Santa Cruz, sc-95), anti-
OB-cadherin (H-50 Santa Cruz, sc-28643), anti-ezrin (H-276
Santa Cruz, sc-20773), anti-merlin (C-18 Santa Cruz, sc-332; and
A-19, Santa Cruz, sc-331), anti-a-tubulin (Oncogene, #CP06),
and anti-GAPDH (Calbiochem #CB1001). The merlin phospho-
specific antibody was provided by Joseph Kissil.
Quantitative real-time RT-PCR
Total RNA was extracted and purified using the RNeasy kit
(Qiagen, Valencia, CA), followed by DNase treatment. One mgo f
RNA was reverse transcribed using the iScript cDNA synthesis kit
(BioRad, Hercules, CA), according to manufacturer’s instructions.
Pak1, Rac1, OB-cadherin, N-cadherin, and b-catenin mRNA
expression levels were determined using TaqManH Assay (Applied
Biosystems, Carlsbad, CA). Briefly, 50 ng of cDNA were subjected
to 50 cycles of quantitative PCR in an iCycler (BioRad) using
TaqManH Universal Mastermix according to the manufacturers’
instructions. Samples were normalized to the GAPDH reference
gene and relative expression levels of all genes were determined
using the
DDCt method. TaqManH assays used for these studies
were: Pak1 (Mm0044612_m1), Rac1 (Mm00488847_m1), OB-
cadherin (Mm00515462_m1), N-cadherin (Mm00483213_m1), b-
catenin (Mm00499427_s1), and GAPDH (Mm00483213_m1).
Sample processing for microarray analysis
A mouse genome 430 2.0 microarray chip was used for this
study. Five micrograms of total RNA from each sample were
processed for microarray analysis. Samples were generated and
processed in triplicate. Poly(A) RNA was converted to cDNA and
then amplified and labeled with biotin as described by Van Gelder
et al. [51]. Hybridization with the biotin-labeled RNA, staining,
and scanning of the chips followed the prescribed procedure
outlined in the Affymetrix technical manual. Microarray data are
MIAME compliant and the raw data were deposited in the
National Center for Biotechnology Information Gene Expression
Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/), which is a
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website (http://www.mged.org/Workgroups/MIAME/miame.
html). Accession number for our microarray data is GSE19299.
Microarray data analysis
Scanned output files were visually inspected for hybridization
artifacts and then analyzed using Affymetrix Microarray 5.0
software. Signal intensity was scaled to a trimmed mean intensity
of 500 (MAS5) prior to output. Microarray data quality, checked
by Chip-wise Correlation Plot [52], was found to be satisfactory.
Statistical analyses for individual genes and pathways were
performed on 1719 cell adhesion-related genes (Gene Ontology
database, http://www.geneontology.org) as well as the Chip-wise
genes. MetaCore (version 5.3 build 18499, GeneGo, Hollywood,
FL), SAM and SAM-GSA software (http://www-stat.stanford.
edu/˜tibs/SAM/), and Gene Set Enrichment Analysis (GSEA,
http://www.bioconductor.org/) were used to analyze individual
genes and gene sets. For individual genes, tests of statistical
significance between wild-type and pRb-deficient samples were
conducted using Wilcoxon tests; permutation number was set to
no less than 500, false discovery rate (FDR) was strictly set under
5%, and fold change was used to determine the quantity of genes
included in the final outcome. Annotations of multiple gene
databases were downloaded from the Affymetrix website accord-
ing to the chip model (see supplemental materials). Genes of
interest were selected from output genes. We determined qPCR
assay eligibility by using UCSC genome browser to confirm
specific position, transcriptional direction and consensus of
multiple databases, including RefSeq, Uniprot, GenBank, and
Comparative Genomics. Target gene sequences for qPCR were
obtained from NetAffx module of Affymetrix website. For cellular
pathway analysis, MetaCore is based on hypergeometric distribu-
tion, SAM-GSA uses ‘‘Maxmean’’ statistic, and GSEA uses
modified Kolmogorov-Smirnov statistic. Gene sets were retri-
eved from http://www.broad.mit.edu/gsea/msigdb/collections.
jsp, and biological process ontology subset was selected based on
information described in http://www.geneontology.org/GO.
process.guidelines.shtml.
Validation of microarray data
Microarray data were validated with quantitative real-time
quantitative PCR (qRT-PCR), performed using the BioRad iQ
S Y B RG r e e nS u p e r m i xo naM y i QS i n g l eC o l o rr e a l - t i m eP C R
detection system. Primers used are available upon request.
Selected genes from the microarray analysis were validated by
qRT-PCR. Briefly, RNA prepared for microarray from MC3T3
Rb+/+ and MC3T3 Rb2/2 cells was reverse transcribed using
iScript cDNA synthesis kit fromB i o R a d .T h ec D N Aw a sd i l u t e d
1:30 and qRT-PCR was performed with 1.5–3.0 mLc D N Ai na
25-mL final volume in triplicates on 96-well plates, using BioRad
SYBR green on the MyiQ PCR detection system. We used the
following mouse primer pairs: cdh13, 59-cagaatcaatgagaaca-
cagg-39 (f) and 59-atcacaatgacttccagagg-39 (r); podxl2, 59-
tgggaagaagaggaactaaa-39 (f) and 59-ctcagtcaggtctgggaag-39 (r);
ret, 59-tggcacacctctgctctatg-39 (f) and 59-gcggatccagtcattctcat-39
(r); rnd1, 59-tgtcccaccagaagcaggcaccca-39 (f) and 59-cggaagt-
gaaagccgagccctccaggt-39 (r); msln, 59-aggatagccttgtgggtag-39 (f)
and 59-aacgagattcccttcaccta-39 (r); cdh26, 59-tgggatggcaacgag-
gaggg-39 (f) and 59-acaacgacgaggctatgggc-39 (r); panx3, 59-
cccccaagtccccattctcagcagc-39 (f) and 59-tgcggtcaggcagcagggca-39
(r); wisp2, 59-gtggtgctgtgtgcctctt-39 (f) and 59-aaggtctccccatc-
caggta-39 (r); cadherin1/E-cadherin/CDH1,5 9-gctggaccgagagagt-
tacc-39 (f) and 59-tgttgtgctcaagccttcac-39 (r); rnd3, 59-
cgtccgtccactctcttaccca-39 (f) and 59-tgcagcccaccaacagcatc-39 (r);
ctnnal1, 59-tggcgagggctgtgcttgaa-39 (f) and 59-tccgtgaccttctc-
cagggc-39 (r); ctnnd1, 59-agactgggctattctctgtg-39 (f) and 59-
gggcaggataaaaagtaagg-39 (r); nf2, 59-ggggctaagagacccagaac-39
(f) and 59-aagaaccaggtttcccgaag-39 (r); vcl, 59-gcacatctgacc-
tactgctt-39 (f) and 59-ccactacctctgccactgta-39 (r); rasa1, 59-
gcgtttttcttcactctcag-39 (f) and 59-cgccttctatcttctactgg-39 (r); mtdh,
59-gttaccaccgagcaacttac-39 (f) and 59-agattttcattcagccttga-39
(r); mcam, 59-aaactggtgtgcgtcttct-39 (f) and 59-tactggctgcttttcc-
tct-39 (r).
Supporting Information
Figure S1 pRb-deficient osteoblasts show traits of the trans-
formed phenotype. (a) To determine if pRb-deficient MC3T3
osteoblasts are able to form tumors in vivo, 16106 cells were
injected subcutaneously into SCID/NCr BALB/C mice. Three
weeks after injection, mice injected with pRb-deficient MC3T3
osteoblasts developed highly vascularized tumors (arrow), while no
tumors were apparent in mice injected with pRb-expressing
MC3T3 controls. (b) While pRb-expressing MC3T3 osteoblasts
were unable to grow in soft agarose and remained as single cells
(left), pRb-deficient MC3T3 osteoblasts were able to proliferate to
form cell colonies in soft agar (right), indicating that they have the
capacity to grow in an anchorage-independent manner. Magni-
fication is 10X, bar=20 mm.
Found at: doi:10.1371/journal.pone.0013954.s001 (6.32 MB TIF)
Figure S2 Knock-down of endogenous pRb in pRb-expressing
osteoblasts disrupts adherens junctions. A DNA construct
encoding a short hairpin-interfering RNA targeting the mouse
RB gene (RB-shRNA) was cloned into an expression vector. pRb-
expressing MC3T3 cells were then transfected with this construct
followed by selection of stable transfectants. (a). Phase contrast
micrographs at 4x showing that pRb-expressing MC3T3 in which
pRb expression is suppressed by RB-shRNA (right) grow to a
higher cell density when compared to pRb-expressing MC3T3
cells transfected with control vector (left). Bar=2 mm. (b)
Immunocytochemical localization of pRb and b-catenin in pRb-
expressing MC3T3 osteoblasts transfected with control vector (left)
showed nuclear immunoreactivity for pRb (green) and membrane-
associated immunoreactivity for b-catenin (red). Immunocyto-
chemical analysis of pRb-expressing MC3T3 cells transfected with
the RB-shRNA (middle) showed a strong correlation between pRb
and b-catenin expression in these cultures, pRb and b-catenin
expression being undetectable in the same cells. Total nuclei
stained with DAPI (blue) are shown in the right panel,
magnification is 1006, bar=1 mm.
Found at: doi:10.1371/journal.pone.0013954.s002 (6.53 MB TIF)
Figure S3 pRb regulates merlin folding in human osteoblasts.
To determine if pRb expression is necessary and sufficient to
promote merlin activation, we investigated merlin-tubulin inter-
actions in the pRb-deficient osteosarcoma cell line Saos-2. Saos-2
cells were transfected with either control vector (CV) or with a
vector transducing pRb. Cells transfected with control vector and
pRb-transfected cells were cultured for 2, 5, 7, and 10 days
following transfection and harvested to obtain whole protein
lysates. Merlin was immunoprecipitated from these lysates using a
merlin-specific antibody, followed by immunoblot analysis using
antibodies against merlin and a-tubulin. Merlin is predominantly
co-immunoprecipitated with a-tubulin in CV-transfected cells,
while this interaction is significantly diminished as early as 2 days
after pRb reintroduction, suggesting that merlin is activated soon
after pRb reintroduction into Saos-2 cells.
Found at: doi:10.1371/journal.pone.0013954.s003 (6.53 MB TIF)
pRb and Cell Adhesion
PLoS ONE | www.plosone.org 14 November 2010 | Volume 5 | Issue 11 | e13954Figure S4 Blocking Rac1 activity reestablishes adherens junc-
tion formation and contact-dependent growth arrest. In these
experiments, pRb-expressing osteoblasts stably expressing dnCdk5
were transfected with either a control vector or a dominant
negative Rac1 (RacN17), followed by selection of stable transfec-
tants. A–B. Phase contrast photomicrographs at 46magnification
(bar=2 mm) (A) and growth curve analysis (B) showing that pRb-
expressing osteoblasts stably expressing dnCdk5 and RacN17 grew
in culture to a lower cell density than dnCdk5-expressing
osteoblasts transfected with control vector (CV). In each graph
each data point represents the mean of three independent
experiments 6 standard error. (c) Immunocytochemical localiza-
tion of b-catenin showing that its membrane-associated localiza-
tion is partially reestablished in pRb-expressing osteoblasts
expressing both dnCdk5 and RacN17. Magnification is 1006,
bar=1 mm. (d) Crystal violet staining showing reduced number of
foci in pRb-expressing osteoblasts expressing both dnCdk 5 and
RacN17.
Found at: doi:10.1371/journal.pone.0013954.s004 (2.30 MB TIF)
Table S1 pRb deficiency dramatically affects the expression of
genes involved in cell adhesion pathways in osteoblasts. MetaCore
cellular pathway analysis in conjunction with the Canonical
Pathway database from GeneGO Inc. were used to determine
which canonical pathways are statistically affected by pRb
deficiency. This analysis allowed us to determine the relative
position of cell-adhesion-related cellular pathways within all the
cellular pathways regulated by pRb. Analyses based on the
GeneGO database yielded 139 cellular processes (out of 289 total
cellular processes) that were significantly affected by pRb
expression (P.0.05 and false discovery rate (FDR) ,0.0175).
Remarkably, 8 of the top 10 cellular processes affected by pRb
expression are all related to cell adhesion. Blue shading indicates
the cut off of statistical significance. This table summarizes results
from several microarray analyses, all of which indicate that pRb
dramatically affects expression of genes involved in cell adhesion.
It is noteworthy that cell cycle does not appear prominently in the
pathways regulated by pRb in these cells. This may not come as a
surprise as the cell lines used (pRb-expressing and pRb-deficient)
were harvested during the proliferative phase of growth, thus
minimizing the well-known effects of pRb on cell cycle
progression.
Found at: doi:10.1371/journal.pone.0013954.s005 (0.26 MB
XLS)
Table S2 Cell Adhesion Related Genes Positively Regulated by
Rb. Gene Ontology database prioritization for cell adhesion genes
yielded 1719 individual probe-sets corresponding to genes
designated to be involved directly or indirectly in cell adhesion.
This table shows those that were positively regulated by pRb. For
these 1719 individual probesets, tests for magnitudes in changes in
gene expression between pRb-expressing and pRb-deficient
osteoblasts as well as for statistical significance of these changes
were conducted using SAM software running the Wilcoxon
algorithm. Out of 1719 cell-adhesion related probe-sets, 1054
(61%) were significantly altered by pRb with a false discovery rate
(FDR) of ,0.0320 (FDR ,0.05 is considered statistically
significant). Of these 1054 genes, 462 (27%) were altered at least
two-fold by pRb (FDR=0.0219). As an example, OB-cadherin
(encoded by the cdh11 gene) is among these genes and is down-
regulated 4.45-fold in pRb-deficient cells. One-hundred and
thirty-seven genes (8%) and 63 genes (4%) were altered by at
least 5- and 10-fold, with FDRs of 0.0041 and 0.0001, respectively,
by pRb expression. Together, these results show that pRb
dramatically affects the transcription of a wide array of cell
adhesion genes.
Found at: doi:10.1371/journal.pone.0013954.s006 (0.48 MB
XLS)
Table S3 Cell Adhesion Related Genes Negatively Regulated by
Rb. Description for this table is the same as for Table S2, except
that this table highlights genes repressed by pRb.
Found at: doi:10.1371/journal.pone.0013954.s007 (0.33 MB
XLS)
Table S4 GeneGo Analysis. Analyses based on the GO database
from the GO project confirmed the results from the Canonical
Pathway Database shown in table S1 by ranking a cell-adhesion
process with the second best P value among a total of 3752 GO
functional processes. These data demonstrate, in an arbitrary
fashion, that cell adhesion processes are among those most
significantly affected by pRb.
Found at: doi:10.1371/journal.pone.0013954.s008 (1.71 MB
XLS)
Table S5 Gene Set Analysis (GSA, one module of SAM). GSA
was performed using GO Project database. Results indicated
that pRb knockout would significantly affect adhesion related
processes.
Found at: doi:10.1371/journal.pone.0013954.s009 (0.01 MB
XLS)
Table S6 Gene Set Enrichment Analysis (GSEA, one module of
SAM). GSEA was performed using GO Project database. Results
again indicated that pRb knockout would significantly affect
adhesion related processes.
Found at: doi:10.1371/journal.pone.0013954.s010 (0.01 MB
XLS)
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